|
Eugene J. Segre, M.D.
Pharmaceutical Development Advisor
Former Syntex (now Roche Bioscience) Executive
Dr. Eugene Segre, a board certified internist and endocrinologist, has been
an advisor in drug development, primarily serving early stage biotech and
pharmaceutical companies, since 1990. He has provided expert assistance in
many phases of drug development from the overall planning of development
programs to the design and implementation of clinical trials in a wide range
of therapeutic areas.
Dr. Segre investigated female reproduction at the Worcester Foundation for
Experimental Biology and in 1964 joined the Syntex Corporation. In his
26-year career at Syntex, Dr. Segre successfully filled the roles of
Director of Clinical Pharmacology, Vice-President and Medical Director ,and
Senior Vice-President and Director of Development Research.
In his ten years in the latter role he had worldwide responsibility for the
disciplines of medicine, pharmaceutical science, metabolic research,
toxicology, biostatistics and data management as well as the project
planning and management group. He directed the evaluation and development of
48 new chemical entities (NCEs) and managed more than 60 project teams.
Thirty-two of these NCEs progressed to clinical trials and U.S. New Drug
Applications (NDAs) were approved for eight of them, among them ketorolac,
ticlopidine, nafarelin, ganciclovir, and sulconazole.
Dr. Segre is the author or co-author of over 50 scientific papers, a number
of textbook chapters and a monograph. He is the inventor of several patents.
Dr. Segre received his B.A. with distinction and M.D. degrees from Cornell
University.
|
 |
